These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24468235)

  • 1. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals.
    Hall G; Neighbors CJ; Iheoma J; Dauber S; Adams M; Culleton R; Muench F; Borys S; McDonald R; Morgenstern J
    J Subst Abuse Treat; 2014 Apr; 46(4):511-5. PubMed ID: 24468235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
    Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
    J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention in methadone and buprenorphine treatment among African Americans.
    Gryczynski J; Mitchell SG; Jaffe JH; Kelly SM; Myers CP; O'Grady KE; Olsen YK; Schwartz RP
    J Subst Abuse Treat; 2013 Sep; 45(3):287-92. PubMed ID: 23566446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
    Madden L; Bojko MJ; Farnum S; Mazhnaya A; Fomenko T; Marcus R; Barry D; Ivanchuk I; Kolomiets V; Filippovych S; Dvoryak S; Altice FL
    Int J Drug Policy; 2017 Nov; 49():48-53. PubMed ID: 28957756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.
    Krans EE; Kim JY; James AE; Kelley D; Jarlenski MP
    Obstet Gynecol; 2019 May; 133(5):943-951. PubMed ID: 30969219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder.
    Feder KA; Krawczyk N; Saloner B
    J Adolesc Health; 2017 Jun; 60(6):747-750. PubMed ID: 28258807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.
    Saloner B; Stoller KB; Barry CL
    Psychiatr Serv; 2016 Jun; 67(6):676-9. PubMed ID: 26927578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L; Larance BK; Bell JR; Winstock AR; Lintzeris N; Ali RL; Scheuer N; Mattick RP
    Med J Aust; 2009 Aug; 191(3):161-5. PubMed ID: 19645647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.